[胸腺上皮肿瘤分子靶向治疗的研究现状]
[Research status of molecular targeted therapy in thymic epithelial tumors].
作者信息
Chen Lizhu, Wu Kailiang
机构信息
Department of Radiation Oncology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China; Fujian Provincial Cancer Hospital, Fuzhou 350014, China.
Department of Radiation Oncology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
出版信息
Zhongguo Fei Ai Za Zhi. 2014 Jun 20;17(6):487-90. doi: 10.3779/j.issn.1009-3419.2014.06.09.
Abstract
In recent years, as the study of molecular mechanism and signal transduction pathways of tumors, molecular target therapy in many solid tumors has made great progress. At present, more and more studies focus on molecular target drugs in thymic epithelial tumors and people have got some experience. Molecular target therapy may be a new therapeutic option for patients of thymic epithelial tumor.
摘要
近年来，随着肿瘤分子机制和信号转导通路研究的开展，分子靶向治疗在多种实体瘤中取得了很大进展。目前，越来越多的研究聚焦于胸腺上皮肿瘤的分子靶向药物，并且人们已经获得了一些经验。分子靶向治疗可能是胸腺上皮肿瘤患者的一种新的治疗选择。
相似文献
1
[Research status of molecular targeted therapy in thymic epithelial tumors].[胸腺上皮肿瘤分子靶向治疗的研究现状]
Zhongguo Fei Ai Za Zhi. 2014 Jun 20;17(6):487-90. doi: 10.3779/j.issn.1009-3419.2014.06.09.
2
Available evidence and new biological perspectives on medical treatment of advanced thymic epithelial tumors.有关晚期胸腺癌治疗的现有证据和新的生物学视角。
Ann Oncol. 2015 May;26(5):838-847. doi: 10.1093/annonc/mdu527. Epub 2014 Nov 19.
3
Precise Diagnosis and Treatment of Thymic Epithelial Tumors Based on Molecular Biomarkers.基于分子生物标志物的胸腺上皮肿瘤的精准诊断与治疗
Crit Rev Oncog. 2017;22(5-6):507-514. doi: 10.1615/CritRevOncog.2017020577.
4
PI3K as a Potential Therapeutic Target in Thymic Epithelial Tumors.PI3K作为胸腺上皮肿瘤的潜在治疗靶点
J Thorac Oncol. 2016 Aug;11(8):1345-1356. doi: 10.1016/j.jtho.2016.04.013. Epub 2016 Apr 24.
5
Where do immune checkpoint inhibitors stand in the management of thymic epithelial tumors?免疫检查点抑制剂在胸腺上皮肿瘤的治疗中处于什么地位？
Immunotherapy. 2018 Aug;10(10):823-826. doi: 10.2217/imt-2018-0069.
6
Current Drug Targets for Thymic Neoplasms.胸腺瘤的当前药物靶点
Curr Cancer Drug Targets. 2015;15(7):593-603. doi: 10.2174/1568009615666150616124155.
7
Targeted therapy for thymic epithelial tumors: a new horizon? Review of the literature and two cases reports.胸腺瘤的靶向治疗：新的前景？文献综述及两例病例报告
Future Oncol. 2015;11(8):1223-32. doi: 10.2217/fon.14.318.
8
Thymic epithelial tumors express vascular endothelial growth factors and their receptors as potential targets of antiangiogenic therapy: a tissue micro array-based multicenter study.胸腺上皮肿瘤表达血管内皮生长因子及其受体作为抗血管生成治疗的潜在靶点：一项基于组织微阵列的多中心研究。
Lung Cancer. 2014 Aug;85(2):191-6. doi: 10.1016/j.lungcan.2014.05.010. Epub 2014 May 22.
9
Imatinib mesylate in thymic epithelial malignancies.甲磺酸伊马替尼治疗胸腺瘤上皮性肿瘤。
Cancer Chemother Pharmacol. 2012 Feb;69(2):309-15. doi: 10.1007/s00280-011-1690-0. Epub 2011 Jun 28.
10
Epidermal growth factor receptor, C-kit, and Her2/neu immunostaining in advanced or recurrent thymic epithelial neoplasms staged according to the 2004 World Health Organization in patients treated with octreotide and prednisone: an Eastern Cooperative Oncology Group study.根据 2004 年世界卫生组织标准分期的晚期或复发性胸腺瘤上皮性肿瘤患者接受奥曲肽和泼尼松治疗后的表皮生长因子受体、C-kit 和 Her2/neu 免疫组化：东部肿瘤协作组研究。
J Thorac Oncol. 2010 Jun;5(6):885-92. doi: 10.1097/JTO.0b013e3181d86a30.
本文引用的文献
1
Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial.西妥昔单抗治疗复发性或难治性晚期胸腺癌患者的多中心、开放标签、2 期临床试验。
Lancet Oncol. 2014 Feb;15(2):191-200. doi: 10.1016/S1470-2045(13)70596-5. Epub 2014 Jan 15.
2
A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors.一项吉西他滨联合达沙替尼治疗晚期实体瘤患者的 1 期研究。
Invest New Drugs. 2013 Aug;31(4):918-26. doi: 10.1007/s10637-012-9898-3. Epub 2012 Nov 20.
3
Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors.激活一组胸腺癌中的 c-KIT 突变和对不同 c-KIT 抑制剂的反应。
Ann Oncol. 2012 Sep;23(9):2409-2414. doi: 10.1093/annonc/mdr626. Epub 2012 Feb 21.
4
[A response to erlotinib hydrochloride in the case of post-operative recurrent thymoma].[盐酸厄洛替尼治疗术后复发性胸腺瘤1例报告]
Gan To Kagaku Ryoho. 2011 Nov;38(12):2200-1.
5
Imatinib mesylate in thymic epithelial malignancies.甲磺酸伊马替尼治疗胸腺瘤上皮性肿瘤。
Cancer Chemother Pharmacol. 2012 Feb;69(2):309-15. doi: 10.1007/s00280-011-1690-0. Epub 2011 Jun 28.
6
Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors.贝林司他治疗复发性或难治性晚期胸腺癌患者的 II 期研究。
J Clin Oncol. 2011 May 20;29(15):2052-9. doi: 10.1200/JCO.2010.32.4467. Epub 2011 Apr 18.
7
Promising efficacy of sorafenib in a relapsed thymic carcinoma with C-KIT exon 11 deletion mutation.索拉非尼治疗伴有 C-KIT 外显子 11 缺失突变的复发性胸腺癌的疗效确切。
Lung Cancer. 2011 Jan;71(1):109-12. doi: 10.1016/j.lungcan.2010.09.011.
8
Thymic tumors: relevant molecular data in the clinic.胸腺肿瘤：临床相关的分子数据。
J Thorac Oncol. 2010 Oct;5(10 Suppl 4):S291-5. doi: 10.1097/JTO.0b013e3181f209b9.
9
Insulin-like growth factor-1 receptor expression in thymic malignancies.胰岛素样生长因子-1 受体在胸腺癌中的表达。
J Thorac Oncol. 2010 Sep;5(9):1439-46. doi: 10.1097/JTO.0b013e3181e392a8.
10
Phase I trial of SU14813 in patients with advanced solid malignancies.SU14813 在晚期实体瘤患者中的 I 期临床试验。
Ann Oncol. 2011 Jan;22(1):195-201. doi: 10.1093/annonc/mdq313. Epub 2010 Jul 6.
Zotero 插件